Updated analysis with additional FU of EV 302 EV+P in 1st line advanced #BladderCancer
✅ PFS & OS benefit in all groups
✅ Benefit in cisplatin eligible/ineligible
✅ Safety consistent with prior analysis
✅ mDOR close to 2 years #ascoGU25 @oncodaily.bsky.social
✅ PFS & OS benefit in all groups
✅ Benefit in cisplatin eligible/ineligible
✅ Safety consistent with prior analysis
✅ mDOR close to 2 years #ascoGU25 @oncodaily.bsky.social
1 / 4
Comments